1. Home
  2. EVF vs MGNX Comparison

EVF vs MGNX Comparison

Compare EVF & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eaton Vance Senior Income Trust

EVF

Eaton Vance Senior Income Trust

N/A

Current Price

$5.01

Market Cap

95.9M

Sector

Finance

ML Signal

N/A

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

N/A

Current Price

$3.33

Market Cap

115.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EVF
MGNX
Founded
N/A
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
95.9M
115.8M
IPO Year
1998
2013

Fundamental Metrics

Financial Performance
Metric
EVF
MGNX
Price
$5.01
$3.33
Analyst Decision
Hold
Analyst Count
0
5
Target Price
N/A
$3.40
AVG Volume (30 Days)
82.6K
1.3M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$149,500,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.77
$0.99
52 Week High
$5.96
$3.50

Technical Indicators

Market Signals
Indicator
EVF
MGNX
Relative Strength Index (RSI) 27.69 87.97
Support Level N/A $1.42
Resistance Level $5.35 N/A
Average True Range (ATR) 0.05 0.18
MACD -0.01 0.15
Stochastic Oscillator 15.52 91.34

Price Performance

Historical Comparison
EVF
MGNX

About EVF Eaton Vance Senior Income Trust

Eaton Vance Senior Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to provide a high level of current income consistent with the preservation of capital, by investing in senior, secured floating-rate loans. The trust invests in below-investment-grade floating-rate loans, which are considered speculative because of the credit risk of their issuers. Its portfolio of investment consists of aerospace and defense, automotive, beverage, building and development, business equipment and services, cable and satellite television, and other areas.

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Share on Social Networks: